RT journal article
T1 Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
A1 Mas, Sergi
A1 Julià, Laura
A1 Cuesta, Manuel J.
A1 Crespo Facorro, Benedicto
A1 Vázquez Bourgon, Javier
A1 Spuch, Carlos
A1 González-Pinto, Ana
A1 Ibáñez, Angela
A1 Usall, Judith
A1 Romero López Alberca, Cristina
A1 Catalan, Ana
A1 Mané, Anna
A1 Bernardo, Miquel
A2 Psicología
K1 antipsychotic
K1 personalized medicine
K1 Pharmacogenetics
K1 prediction
K1 psychosis
AB The application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. Here, we describe the rationale, aims and methodology of Applied Pharmacogenetics to Predict Response to Treatment of First Psychotic Episode (the FarmaPRED-PEP project), which aims to develop and validate predictive algorithms to classify FEP patients according to their response to antipsychotics, thereby allowing the most appropriate treatment strategy to be selected. These predictors will integrate, through machine learning techniques, pharmacogenetic (measured as polygenic risk scores) and epigenetic data together with clinical, sociodemographic, environmental, and neuroanatomical data. To do this, the FarmaPRED-PEP project will use data from two already recruited cohorts: the PEPS cohort from the “Genotype-Phenotype Interaction and Environment. Application to a Predictive Model in First Psychotic Episodes” study (the PEPs study from the Spanish abbreviation) (N=335) and the PAFIP cohort from “Clinical Program on Early Phases of Psychosis” (PAFIP from the Spanish abbreviation) (N = 350). These cohorts will be used to create the predictor, which will then be validated in a new cohort, the FarmaPRED cohort (N = 300). The FarmaPRED-PEP project has been designed to overcome several of the limitations identified in pharmacogenetic studies in psychiatry: (1) the sample size; (2) the phenotype heterogeneity and its definition; (3) the complexity of the phenotype and (4) the gender perspective. The global reach of the FarmaPRED-PEP project is to facilitate the effective deployment of precision medicine in national health systems.
PB Frontiers Media SA
SN 1664-0640
YR 2024
FD 2024
LK http://hdl.handle.net/10498/37032
UL http://hdl.handle.net/10498/37032
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 21-sep-2026